10 Best Short-Term Stocks To Buy Right Now

3. Regulus Therapeutics Inc. (NASDAQ:RGLS)

Last 52 weeks return: -39.34%

Last 1 month’s return: 22.31%

No. of hedge fund portfolios: 13

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company specializing in microRNA-based therapies for kidney and liver diseases. The company operates from its headquarters located in California, United States. Its drug pipeline targets conditions such as chronic kidney disease and rare genetic disorders. Differentiation in the market is achieved through a proprietary focus on RNA-targeted therapeutics.

Regulus Therapeutics Inc. (NASDAQ:RGLS) has struggled over the past year, as evidenced by a 39.34% decline. The drop came even after receiving positive results from a Phase 1b interim analysis on ADPKD patients. Emphasis was laid on the phase 3 trial since phase 1 does not establish the drug’s effectiveness and safety.

However, the recent performance suggests a potential turnaround, as the stock gained 22.31% over the last month. Phase 3 trial began in the previous quarter and is anticipated to enroll 336 adults. The trial attracts potential investors interested in the biopharmaceutical market, and hence, it has received appreciation for the value of its stocks in recent times. The 20-day SMA grew by 11.61%, against the 200-day SMA of -7.35%.

With 13 hedge funds holding positions in Q4 2024, investor confidence is growing, pointing out Regulus as a compelling addition to the best short-term stock investment watchlist.